Cargando…

Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy

This paper demonstrates that the introduction of large-core needle biopsy (LCNB) replacing needle-localised breast biopsy (NLBB) for nonpalpable (screen-detected) breast lesions could result in substantial cost savings at the expense of a possible slight increase in breast cancer mortality. The cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Groenewoud, J H, Pijnappel, R M, van den Akker-van Marle, M E, Birnie, E, Buijs-van der Woude, T, Mali, W P Th M, de Koning, H J, Buskens, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409541/
https://www.ncbi.nlm.nih.gov/pubmed/14735181
http://dx.doi.org/10.1038/sj.bjc.6601520
_version_ 1782155792020930560
author Groenewoud, J H
Pijnappel, R M
van den Akker-van Marle, M E
Birnie, E
Buijs-van der Woude, T
Mali, W P Th M
de Koning, H J
Buskens, E
author_facet Groenewoud, J H
Pijnappel, R M
van den Akker-van Marle, M E
Birnie, E
Buijs-van der Woude, T
Mali, W P Th M
de Koning, H J
Buskens, E
author_sort Groenewoud, J H
collection PubMed
description This paper demonstrates that the introduction of large-core needle biopsy (LCNB) replacing needle-localised breast biopsy (NLBB) for nonpalpable (screen-detected) breast lesions could result in substantial cost savings at the expense of a possible slight increase in breast cancer mortality. The cost-effectiveness of LCNB and NLBB was estimated using a microsimulation model. The sensitivity of LCNB (0.97) and resource use and costs of LCNB and NLBB were derived from a multicentre consecutive cohort study among 973 women who consented in getting LCNB and NLBB, if LCNB was negative. Sensitivity analyses were performed. Replacing NLBB with LCNB would result in approximately six more breast cancer deaths per year (in a target population of 2.1 million women), or in 1000 extra life-years lost from breast cancer (effect over 100 years). The total costs of management of breast cancer (3% discounted) are estimated at £4676 million with NLBB; introducing LCNB would save £13 million. The incremental cost-effectiveness ratio of continued NLBB vs LCNB would be £12 482 per additional life-year gained (3% discounted); incremental costs range from £-21 687 (low threshold for breast biopsy) to £74 378 (high sensitivity of LCNB).
format Text
id pubmed-2409541
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24095412009-09-10 Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy Groenewoud, J H Pijnappel, R M van den Akker-van Marle, M E Birnie, E Buijs-van der Woude, T Mali, W P Th M de Koning, H J Buskens, E Br J Cancer Clinical This paper demonstrates that the introduction of large-core needle biopsy (LCNB) replacing needle-localised breast biopsy (NLBB) for nonpalpable (screen-detected) breast lesions could result in substantial cost savings at the expense of a possible slight increase in breast cancer mortality. The cost-effectiveness of LCNB and NLBB was estimated using a microsimulation model. The sensitivity of LCNB (0.97) and resource use and costs of LCNB and NLBB were derived from a multicentre consecutive cohort study among 973 women who consented in getting LCNB and NLBB, if LCNB was negative. Sensitivity analyses were performed. Replacing NLBB with LCNB would result in approximately six more breast cancer deaths per year (in a target population of 2.1 million women), or in 1000 extra life-years lost from breast cancer (effect over 100 years). The total costs of management of breast cancer (3% discounted) are estimated at £4676 million with NLBB; introducing LCNB would save £13 million. The incremental cost-effectiveness ratio of continued NLBB vs LCNB would be £12 482 per additional life-year gained (3% discounted); incremental costs range from £-21 687 (low threshold for breast biopsy) to £74 378 (high sensitivity of LCNB). Nature Publishing Group 2004-01-26 2004-01-20 /pmc/articles/PMC2409541/ /pubmed/14735181 http://dx.doi.org/10.1038/sj.bjc.6601520 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Groenewoud, J H
Pijnappel, R M
van den Akker-van Marle, M E
Birnie, E
Buijs-van der Woude, T
Mali, W P Th M
de Koning, H J
Buskens, E
Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
title Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
title_full Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
title_fullStr Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
title_full_unstemmed Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
title_short Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
title_sort cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409541/
https://www.ncbi.nlm.nih.gov/pubmed/14735181
http://dx.doi.org/10.1038/sj.bjc.6601520
work_keys_str_mv AT groenewoudjh costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT pijnappelrm costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT vandenakkervanmarleme costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT birniee costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT buijsvanderwoudet costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT maliwpthm costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT dekoninghj costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy
AT buskense costeffectivenessofstereotacticlargecoreneedlebiopsyfornonpalpablebreastlesionscomparedtoopenbreastbiopsy